BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study

Abstract

BackgroundBone metastasis (BM) is the most common site of disease in metastatic breast cancer (MBC) patients. BM impacts health-related quality of life (HRQoL). We tested prospectively the psychometric properties of the Bone Metastasis Quality of Life (BOMET-QoL-10) measure on MBC patients with BM.MethodsPatients completed the BOMET-QoL-10 questionnaire, the Visual Analogue Scale (VAS) for pain, and a self-perceived health status item at baseline and at follow-up visits. We performed psychometric tests and calculated the effect size of specific BM treatment on patients´ HRQoL.ResultsAlmost 70% of the 172 patients reported symptoms, 23.3% experienced irruptive pain, and over half were receiving chemotherapy. BOMET-QoL-10 proved to be a quick assessment tool performing well in readability and completion time (about 10 min) with 0–1.2% of missing/invalid data. Although BOMET-QoL-10 scores remained fairly stable during study visits, differences were observed for patient subgroups (e.g., with or without skeletal-related events or adverse effects). Scores were significantly correlated with physician-reported patient status, patient-reported pain, symptoms, and perceived health status. BOMET-QoL-10 scores also varied prospectively according to changes in pain intensity.ConclusionsBOMET-QoL-10 performed well as a brief, easy-to-administer, useful, and sensitive HRQoL measure for potential use for clinical practice with MBC patients.Trial registrationNCT03847220. Retrospectively registered on clinicaltrials.gov (February the 20th 2019).

Measuring Quality of Life Using Patient-Reported Outcomes in Real-World Metastatic Breast Cancer Patients: The Need for a Standardized Approach

“…Results were possibly biased as patients with only visceral metastasis were also included, although biphosphonate treatment is not effective in these cases [ 39 ]. The study of Barnadas et al, a subanalysis of patients receiving specific treatment for bone metastatis versus no treatment revealed clinically significant improvement in HRQoL [ 48 ].…”

Impact and Association of Anaemia Severity and Its Treatment With Quality of Life of Breast Cancer Patients in Malaysia

“…Direct interviews assessing QOL were found to be highly advantageous in guiding healthcare professionals to attain a clear idea about the patient's QOL, to evaluate patient's medical situation and to tailor treatment accordingly so as to avoid medical problem that may negatively affect patient's QOL (35,36) . Barnadas et al, (37) , denotes the necessity to understand impact of cancer disease-associated complications such as anaemia among others, as well as palliative care treatments towards breast cancer patients QOL. Moreover, Chen et al (38) mentions that studies focused on detecting QOL among women suffering from breast cancer is the cornerstone for evaluating clinical situation, clinical decision making as well as health policy or reimbursement decisions.…”

Patient‐reported outcome tools in musculoskeletal oncology

“…Studies have only recently reported on physical function and anxiety levels in cancer patients using these PROMIS-Ca question banks. 64,65 The BOMET-QoL, a musculoskeletal oncologyspecific measure, is a 10-item questionnaire that assesses the subjective and physical aspects of metastatic bone disease to identify changes in the HRQOL in metastatic bone disease patients 66,67 (Table 1). SAM was created as a sarcoma-specific PROM and is a 22-item questionnaire that evaluates the physical, emotional, financial, and social well-being as well as patient sexuality 68 (Table 1).…”